Literature DB >> 29522074

Cure With Cryoablation of Arterial Hypertension Due to a Renin-Producing Tumor.

Giuseppe Maiolino1, Michele Battistel2, Giulio Barbiero2, Valeria Bisogni1, Gian Paolo Rossi1.   

Abstract

BACKGROUND: We herein report on a 20 years old woman with stage I hypertension, who was found to carry a renin-producing tumor (RPT).
METHODS: Due to her young age, the patient underwent screening measurement of plasma renin and aldosterone, abdominal computed tomography (CT) angiography, and selective renal vein renin assessment to identify secondary hypertension.
RESULTS: The patient was screened for secondary causes of hypertension and was diagnosed with secondary aldosteronism. Therefore, she underwent an abdominal computed tomography (CT) angiography that was reported as unremarkable. Selective renal vein renin studies showed overproduction of renin in the right kidney and a re-evaluation of her CT allowed detection of an 8-mm mass in her right kidney, suggesting the presence of a RPT. Considering the technical difficulty of renal sparing surgery a CT-guided cryoablation was undertaken, which provided long-term cure of arterial hypertension and normalization of plasma active renin concentration.
CONCLUSIONS: RPTs usually present with a clinical phenotype featuring stage III and/or malignant hypertension and are held to be exceptionally rare. This case is unique in that it presented with stage I hypertension and a mild clinical phenotype. Moreover, to our knowledge this is the first case of RPTs shown to be safely treated with CT-guided cryoablation and found to be cured at long-term.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29522074     DOI: 10.1093/ajh/hpx213

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  1 in total

1.  The Role of Real-Time Contrast-Enhanced Ultrasound in Guiding Radiofrequency Ablation of Reninoma: Case Report and Literature Review.

Authors:  Rui Zhang; Ming Xu; Xiao-Yan Xie
Journal:  Front Oncol       Date:  2021-02-23       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.